Search
Epicept NP-1
go.drugbank.com/drugs/DB05492InvestigationalEpiCept NP-1 Cream is a patented formulation containing two FDA-approved drugs, amitriptyline (a widely-used antidepressant) and ketamine (an NMDA antagonist that is used as an anesthetic). … Peripheral neuropathies are medical conditions caused by damage to the nerves in the peripheral nervous system.
CG7870
go.drugbank.com/drugs/DB04981InvestigationalCG7870 is an oncolytic virus therapy for prostate cancer. … It is a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
Pentaglobin
go.drugbank.com/drugs/DB15865Investigational[A220173] It is comprised of [immunoglobulin G (IgG)](https://www.drugbank.ca/drugs/DB00028) and immunoglobulin A (IgA) while also being enriched by immunoglobulin M (IgM).[L16353]
Bilastine
go.drugbank.com/drugs/DB11591ApprovedBilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.
Cositecan
go.drugbank.com/drugs/DB05806InvestigationalCositecan is the novel camptothecin derivative which is also known as Karenitecin. It has been developed for superior oral bioavailability and increased lactone stability. It is used to treat cancer.
CYP-001
go.drugbank.com/drugs/DB15739InvestigationalThe MCA-derived MSCs can be obtained from induced pluripotent stem cells (iPSCs) and then expanded in media. … CYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from the mesoderm.
Mebhydrolin
go.drugbank.com/drugs/DB13808InvestigationalMebhydrolin is an antihistamine agent.[A275123]
Activated CDC42 kinase 1
go.drugbank.com/bio_entities/BE0000772TargetHumansContributes to the control of AXL receptor levels. … Implicated in trafficking and clathrin-mediated endocytosis through binding to epidermal growth factor receptor (EGFR) and clathrin.
Synonyms: Tyrosine kinase non-receptor protein 2KOS-2187
go.drugbank.com/drugs/DB05946ExperimentalKOS-2187, a novel erythromycin-based motilin agonist, or motilide, as a clinical candidate for the treatment of gastrointestinal motility disorders such as gastroparesis and gastroesophageal reflux disease (GERD).